Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 1766849

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1766849

Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast

PUBLISHED:
PAGES: 61 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
ZIP (Single User License)
USD 9995
ZIP (Site License)
USD 19990
ZIP (Global License)
USD 29985

Add to Cart

The report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.

NTM refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems. ). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these infections.

Key Highlights

  • Report deliverables include a Pdf report and an Excel-based forecast model
  • Forecast includes the 7 major markets (7MM)
  • Forecast covers the period 2023-2033

Scope

  • Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms.
  • Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Product Code: GDHCOA037

Table of Contents

Table of Contents

1. Preface

  • 1.1. Contents
  • 1.2. Abbreviations
  • 1.3. Related Reports

2. Executive Summary

3. Disease Overview

  • 3.1. Overview of NTM
  • 3.2. NTM Market SWOT Analysis
  • 3.3. Classification of NTM
  • 3.4. NTM Risk Factors

4. Epidemiology

  • 4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-33
  • 4.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-33
  • 4.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 2023
  • 4.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 2023
  • 4.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM
  • 4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM
  • 4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM
  • 4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM
  • 4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM

5. Current Treatment Options

  • 5.1. PNTM Diagnostic Paradigm
  • 5.2. Treatment Paradigm
  • 5.3. Current Treatment Options

6. Unmet Needs and Opportunities

  • 6.1. Unmet Needs in NTM
  • 6.2. New Therapeutic Options with Improved Efficacy
  • 6.3. Improved Diagnostic Methods
  • 6.4. Improved Clinical Trials

7. R&D Strategies

  • 7.1. Trends in Clinical Trial Design in NTM
  • 7.2. Trends in Deal-Making in NTM

8. Pipeline Assessment

  • 8.1. NTM Pipeline Overview
  • 8.2. Late-Stage Pipeline Products for NTM
  • 8.3. NTM Clinical Trials (Phase II/III) Overview

9. Market Outlook

  • 9.1. NTM Market Forecast
  • 9.2. PNTM Market Forecast
  • 9.3. DNTM Market Forecast
  • 9.4. Market Drivers and Barriers

10. Appendix

  • 10.1. Primary Research: KOL Information
  • 10.2. Bibliography
  • 10.3. About the Authors

11. Contact Us

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!